Rapid hep C point-of-care RNA testing and treatment at an integrated supervised consumption service in Toronto, Canada

> Bernadette Lettner Treatment Nurse Toronto Community Hep C Program



HEPC PROGRAM

South Riverdale COMMUNITY HEALTH CENTRE



Acknowledgement and Gratitude





- Gilead Sciences Canada
- In-kind support from Cepheid



Study Objective

- Feasibility of point-of-care RNA testing
- Eligibility: People who inject drugs at keep6 and are not on HCV treatment
- Repeat testing every 3 months for one year, with a final survey at end of protocol





Study Participants (n=125)

Male	66%	
Age (mean)	41 years	
Unstable or no housing	73%	
Daily injection drug use	68%	
Drug injected most frequently	Fentanyl = 50% Crack/Cocaine = 20% Heroin = 14% Prescription opioid = 9% Crystal Meth = 5%	
No past history of HCV testing (no/don't know)	32%	
Received test results same day	100%	South Riverdale COMMUNITY HEALTH CENTRE

Preliminary Results

- Of valid baseline tests: 42% (N=48) were RNA+
- 42 have started additional treatment assessments
 - 2 acute clearance
 - 29 treatment starts with TCHCP
 - 25 SVR
 - 1/29 viremic post-tx
- 7 seroconversions (- \rightarrow +) during f/u testing
 - one spontaneous clearance following seroconversion
 - 5 treated and achieved SVR
- 10 known deaths



Challenges and lessons learned

- Post-test counseling needed beyond the initial test result
- Staff with lived experience of HCV, ongoing access to HCV treatment nurse within the SCS, facilitate linkage to care
- Treatment uptake continues to be limited by drug access (need for chronicity)
- Unexpected benefits: increased use of the SCS, engagement in health care beyond HCV testing



Viral interruption: COVID 19 Pandemic

- Research suspension
 - Disruptions to service interrupted care and follow up
- Decreased access to SCS
 - Decreased capacity at sites
 - Screening and wait times
 - Fewer services definitions of essential
- Staff pulled to other projects
- Cepheid redeployment to hospital for COVID POC testing



Conclusion

- Offering POC RNA testing within an integrated SCS with onsite HCV care is a promising model for HCV engagement
- Immediate results with option for immediate engagement in care
- Support for incident infections



Acknowledgments

- Service users of keep6, and staff
- Kate Mason, Researcher with SRCHC
- Jason Altenberg, Director of Programs & Services, South Riverdale CHC
- Sushi Rosborough, Harm Reduction Worker, keepSIX, SRCHC
- Frank Crichlow, Harm Reduction Worker, SRCHC
- Dr. Jordan Feld, Francis Family Liver Clinic, Toronto General Hospital
- Dr. Jeff Powis, Toronto Community Hep C Program, Michael Garron Hospital
- Erin Mandel, Research Student, UHN
- Other TCHCP program sites: Sherbourne Health, Regent Park Community Health Centre, Parkdale Queen West Community Health Centre



